A series of bis-indole derivatives were designed and synthesized about 10-20% overall yields. Four newly synthesized compounds have not been reported before. Their structures were characterized by 1H NMR. All the synthesized compounds were evaluated for inhibition of cell proliferation of human liver cancer (HepG2), human colon cancer (HT-29) and human leukemia (K562) cell lines activity. The bis-indole showed the inhibition of K562 with IC50 values of 56.19-58.55 μM, respectively.